Sign in
4

Changes in Ownership

ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001209191-23-002114

COO and General Counsel sold 17,500 shares at an average $38.33 ($670,802)

  • COO and General Counsel acquired 65,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

O'Brien Patrick · COO and General Counsel

Table I: Non-derivative

9 lines
Date Transaction Shares Price Value Owned after D/I
2023-01-03 Sale : show line 1 in the form −2,653 $37.53 $99,567 378,222 D
2023-01-03 Sale : show line 2 in the form −5,527 $38.54 $213,011 372,695 D
2023-01-03 Sale : show line 3 in the form −500 $39.74 $19,870 372,195 D
2023-01-03 Sale : show line 4 in the form −70 $40.80 $2,856 372,125 D
2023-01-03 Sale : show line 5 in the form −2,894 $37.58 $108,757 369,231 D
2023-01-03 Sale : show line 6 in the form −5,286 $38.58 $203,934 363,945 D
2023-01-03 Sale : show line 7 in the form −300 $39.55 $11,865 363,645 D
2023-01-03 Sale : show line 8 in the form −270 $40.53 $10,943 363,375 D
2023-01-04 Grant or award : show line 9 in the form +65,000 428,375 D
Open-market sales · 17,500 sh · avg $38.33 · $670,802
Loading xslF345X03/doc4.xml…